This month, Binhui Ni, Head of Partnering & External Innovation (China) of the Global R&D unit of Sanofi aventis, sits down with GBI to share his insights and expertise in doing R&D partnering business in China, tapping on the value and challenges of identifying targets and looking into the commercial opportunities in those potential partners, assets and molecules, among others.

In this month's interview, GBI sits down with Boon Heon Tan, Healthcare Practice Leader at Russell Reynolds Associates Greater China. Boon shares his insights, expertise and experiences about the current landscape of executive search in China in terms of recruiting and retaining outstanding leaders in the life sciences sector. He also shares his knowledge on what type of skill sets are required for senior-level positions in China's growing pharmaceutical/healthcare industry.

In this interview, Professor Ralf Altmeyer, Director General of the Institut Pasteur Shanghai and CEO and Founder of Advance BioChina, shares with us about the creation of Advance BioChina and its role of creating value for global biotech companies in the country. Ralf also shares his insights about the current incubator/accelerator landscape as well as the status of innovative drug discovery/R&D in China

This month, GBI speaks with Dr. Ming-Wei Wang, Director of the National Center for Drug Screening and also a professor at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Ming-Wei shares his expertise, insights, and perspective on current and future trends in China’s drug discovery and development landscape, tapping on major issues involving government-related/sponsored initiatives, innovation, and China as an emerging base for global pharmaceutical companies, among others. He also discusses his role in the creation of the new Chinese National Compound Library, one of the largest academic compound libraries in the world.

This month, GBI sits with Alex Fowkes, former Executive Director and Head of Asia R&D Business Development & Operations at Pfizer and currently working with a number of small companies in the life sciences industry in China as legal consultant. In this interview, Alex shares his industry insights and expertise in biomedical R&D operations, strategy and business development in China

This month, GBI speaks with VP of Procurement Dieter Pfeifer and Rory Budihandojo of the Quality & EHS Audit Group from Boehringer-Ingelheim China. The two share tales collected from over seven years sourcing ingredients for APIs in China and discuss China’s current and future position in the pharmaceutical manufacturing value chain. The company’s technology transfer and center of competence programs, as well as quality audit experience is also discussed in detail.

In this month’s interview, Dr. Dan Zhang, Chairman and CEO of Fountain Medical Development Ltd. shares his experiences and insider’s perspective of the clinical development in China’s pharmaceutical and healthcare space, including his insights about the current downward pressure on drug prices and government’s outpouring of financial support on China’s biotech and pharmaceutical sectors.

In this issue, Herman Schwietert, General Manager of Invida Greater China, shares his experiences and insider’s perspective of the CSO market in China capitalizing on Invida’s strategies for business growth and development. Specifically, Herman taps on key areas of concern including access to Chinese physicians, partnering and sales models, tendering/procurement and detailing to pharmacies, among others.

In this interview, GBI has a conversation with Roberta Lipson, Chairman of United Family Hospitals and co-founder and CEO of Chindex. Roberta discusses the China healthcare sector and provides an overview of current initiatives and future directions at Chindex/United Family, such partnership with Fosun in the medical equipment area and the significant expansion underway at United Family including a new state of the art cancer center.

NULLGBI talks with Paul Boltz, a partner at the Hong Kong office of Ropes & Gray. Paul shares his insider’s perspective on recent transactions and listings in the healthcare space including Microport and Sinopharm. He also discusses a variety of current legal and regulatory issues in the sector such as FCPA and IP considerations and discusses the healthcare business environment and outlook going forward.

This month, Roche Partnering Asia Executive Director Frank Grams sits down with GBI to share with us his experiences and insights about China’s current innovation landscape in the life sciences sector, collaborations as key drivers of innovation as well as Roche strategies in drug delivery partnering.

This month, SinoCure LLC Founder, Chairman and President Wenting Zhang sits down with GBI to discuss a significant role that contract research organizations (CROs) play in the growing healthcare and pharmaceutical industries in China. In this interview, Wenting shares insider insights about the current trends, challenges and coping mechanisms in conducting clinical trials for drugs and devices in the country.

In this interview, Dr. Wan Abdul Rahaman bin Wan Yaacob, Chief Operating Officer of the Malaysian Biotechnology Corporation, the lead development agency for the biotech industry in Malaysia, shares his views on Malaysian-Chinese cooperation in biotechnology and several of the programs the Malaysian government has created to advance life science efforts in the region.

This month, GBI sat down with Andrew Harrison, Regional Life Sciences Practice Leader for China & North Asia for Chubb Commercial Insurance, to talk about the life sciences insurance business - a comparatively new concept for China. In this interview, Andrew discusses risk management, Tort law reform, as well as key differences between the West and China.

This month, Senior Director of Personalized Healthcare Market Development at QIAGEN, Andrew Webb, sits down with GBI to discuss the exciting field of personalized medicine. In this interview, Andrew offers an insider look at new applications for molecular targeting, as well as the role this technology will play in pharmaceutical development in the future.

In this interview, Nisa Leung, partner of Qiming Ventures, shares her insights into how the venture capital landscape for the healthcare area has changed over the years, successful strategies for deal sourcing, and future trends in China’s healthcare market.

GBI sat down with Andreas Amrein, (outgoing) Head of Marketing and Sales Operations for Novartis China, to talk about pharmaceutical commercial sales and promotion-including a comparison of strategies and tactics used here to those in Western markets. Andreas also shares his opinions on medical rep-doctor relations, hospital listings, and the challenges of product launches in China.

John Oyler, founder of recently acquired life science CRO, BioDuro, sits down to discuss the motivation and process behind establishing and growing BioDuro, shares an insider's view of where the CRO industry as a whole is headed, and his future plans. John also offers advice to future would-be entrepreneurs on what it takes to be successful in China and beyond.

This month, GBI sat down with Joseph Tang, Director of Greater China for Smith & Nephew, and former head of Ethicon's global marketing team. In this interview, Joseph offers and in-depth overview of the role he played in attaining Johnson and Johnson's strong foothold in the China market, what it takes to be a successful startup, and possible effects the grassroots medical reform may have on the medical device industry in the future.

Interview with David Pieroni, Managing Director of Automation Quality Solutions (AQS). In this interview David discusses the different GXP regimes in China and overseas and challenges regarding quality assurance and compliance in China. David touches on the CRO, pharmaceutical, API, and device industries, and what to expect in the QA/QC area in China moving forward.

This month, GBI sits down with Dr. Sean Hu, the CEO and Chairman of Beike Biotechnology. In this interview, Dr. Hu discusses the motivation behind his commitment to stem-cell research as well as Beike's current research and clinical application status. He offers a detailed outline of Beike's business model and its future plans as the frontrunner in this up and coming industry.

In this interview IP experts Mark Cohen and Tony Chen shared their deep cumulative experiences from both the policy and practice perspective. In addition to broad patent and trademark issues, Mark and Tony explained the inventor's rights portions of the new patent law, explain the use of China to avoid platform technology patents, and discussed the outlook and forces for change in China's IP regime.

In this interview, Philip Xiao, the co-founder and CDO of Profex Inc, discusses such topics as Profex's struggle to grow from a small startup into a major player in China's dermatology market, the unique challenges facing Profex, anticipated effects of the new medical reform, and the company's future plans.

In this interview, Victor enlightens us on Qiagen's China products and services, the possible impact of the nation's healthcare reform on the molecular diagnostics sector, and the competitive landscape in Qiagen's business segments. Victor also addresses the company’s strategic plan for Asia as well as its past China acquisitions and the challenges associated with integrating those businesses

Interview with Carl Firth, Head of Asia Healthcare at Bank of America-Merrill Lynch. Carl analyzes China’s deal landscape for healthcare, the current investor environment, M&A appetites of both multinationals and domestics, and gives his observations of changes in the sector that have occurred over the past 12 to 18 months.